ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1445

Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States

Lynn Price1, Phil Pouliot 1 and Lauren Schmitt 1, 1Spherix Global Insights, Exton, PA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-TNF therapy, Janus kinase (JAK), Rheumatoid arthritis (RA), small molecules and Biologics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Tofacitinib was the first Janus kinase (JAK) inhibitor FDA approved for the treatment of RA in November 2012, five- and one-half years later, baricitinib, also received approval.  The oral delivery of JAKs make them particularly appealing treatment options for patients with moderate to severe disease, however, many patients still receive a TNF-α-inhibitor in the first-line biologic/JAK treatment setting. With two JAKs available and several JAK entities in clinical development, it is important to understand how US rheumatologists are prescribing these agents in relation to biologics, why patients typically discontinue first-line JAK treatment, and how likely rheumatologists are to prescribe consecutive JAK inhibitors to their RA patients.

Methods: An independent market analytics firm collaborated with US rheumatologists (n=101) to conduct analysis of the RA Market. Data were collected via an online survey fielded in May 2019 and included physician demographics and attitudinal survey responses.

Results: US Rheumatologists estimate that half of their biologic/JAK-treated RA patients are on a first-line agent.  Despite increased advanced treatment options available, TNF-α-inhibitors continue to dominate first-line advanced systemic therapy, with rheumatologists reporting 79% are prescribed a TNF-α-inhibitor prior to JAKs or other biologics. Just 8% are treated with a JAK-inhibitor prior to biologic therapy, though use does significantly increase with each consecutive line of therapy, and 18% and 26% of all second- and third-line biologic/JAK-treated RA patients, respectively, are prescribed either tofacitinib or baricitinib. The most common reasons for pre-biologic JAK discontinuation include primary efficacy failure/lack of initial response (41%) and secondary efficacy failure/waning efficacy over time (29%).  Aspects such as tolerability, safety concerns, and patient adherence also play a role, albeit to a much lesser degree than those related to efficacy. When first-line JAK patients discontinue due to primary efficacy failure they are the most likely to be prescribed a TNF-α-inhibitor in the second-line setting.  Of note, one-quarter of first-line JAK patients who have discontinued due to primary efficacy failure will bypass TNF inhibitor treatment and move from a JAK to the IL-6 inhibitor, tocilizumab.  Only 6% report that when a lack of initial response is at play, they will prescribe a consecutive JAK-inhibitor; however, if a patient discontinues due to waning response, respondents are more likely to cycle JAKs, with 11% of all secondary JAK failures prescribed another JAK. When JAK cycling occurs, it is most often attributed to patient preference for oral treatments.

Conclusion: With two JAK inhibitors currently available in the US RA armamentarium, and several late stage JAKs in development, the relationship and typical treatment protocol for JAK use is important to understand.  Current pre-biologic use of JAKs is limited at just 8% of all first-line patients, though use of the class does increase in later lines of therapy.  Currently, rheumatologists’ propensity to cycle consecutive JAK therapies for the treatment of RA is minimal, and when it does occur, is most commonly patient-driven.


Disclosure: L. Price, None; P. Pouliot, None; L. Schmitt, None.

To cite this abstract in AMA style:

Price L, Pouliot P, Schmitt L. Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/pre-biologic-use-of-janus-kinase-inhibitors-for-the-treatment-of-rheumatoid-arthritis-in-the-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pre-biologic-use-of-janus-kinase-inhibitors-for-the-treatment-of-rheumatoid-arthritis-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology